DDReg pharma

Quailty Driven by Passion

Submit Query

Blogs

Home » Blogs
Role of Placebos in Clinical Trials for Medical Science

Placebos in Clinical Trials: A Fundamental Component of Medical Science 

All Category, Blogs, Clinical Regulatory /

Suppose you are taking a pill, fully aware or sometimes not aware that it contains no active ingredients and yet experiencing an improvement in your symptoms. While this may sound implausible, it illustrates the remarkable reality of the placebo effect an enduring phenomenon that has both puzzled and guided the medical community for centuries. In […]

Placebos in Clinical Trials: A Fundamental Component of Medical Science  Read More »

Current Trends in Advanced Therapies 2025

All Category, Blogs, regulatory /

Breakthroughs in biotechnology are transforming how we approach some of the most challenging medical conditions. Genetic disorders, late-stage cancers, and severe tissue damage are increasingly being treated with therapies tailored to each individual’s unique biology. From gene therapies that rewrite faulty DNA to cell-based treatments that regenerate damaged tissue, advanced therapies are not just reshaping

Current Trends in Advanced Therapies 2025 Read More »

From Waste to Worth: Aligning Your Packaging Strategy with the EU PPWR

All Category, Blogs, regulatory /

Imagine a world where every pill bottle, blister pack, and shipping box not only protects life-saving medications but also safeguards our planet. The PPWR, officially designated as Regulation (EU) 2024/1781, replaces the previous Packaging and Packaging Waste Directive 94/62/EC with a more harmonized approach to packaging sustainability. The EU PPWR Regulation officially entered into force on

From Waste to Worth: Aligning Your Packaging Strategy with the EU PPWR Read More »

Regulatory oversight of companion apps

Regulatory Oversight of Companion Apps: Where Do They Stand? 

All Category, Blogs, Medical Device, regulatory /

Imagine sipping your morning coffee while an app effortlessly syncs with your glucose monitor. These are companion apps, digital tools that extend the functionality of medical devices. But with innovation comes responsibility. So, who ensures these apps are safe, effective, and secure?  Companion apps, particularly in healthcare, are rising fast. But the regulatory frameworks that

Regulatory Oversight of Companion Apps: Where Do They Stand?  Read More »

Expanding to Japan’s Pharma Market? Here’s What You Need to Know

All Category, Blogs, regulatory /

Japan constitutes the world’s third-largest pharmaceutical market, presenting substantial opportunities for companies seeking to expand internationally. With a market size that achieved USD 82.27 billion in 2024 and a projected growth to USD 101.90 billion by 2033, Japan’s pharmaceutical landscape offers both considerable potential and distinct regulatory challenges. However, Japan’s pharmaceutical market is  governed by a

Expanding to Japan’s Pharma Market? Here’s What You Need to Know Read More »

Automating Medical and Scientific Literature Monitoring for Drug Safety

Automation of Literature Monitoring for Pharmacovigilance

All Category, Blogs, Pharmacovigilance /

Literature monitoring, a key component of pharmacovigilance (PV), involves searching and analyzing medical and scientific publications, including journal articles, case reports, conference abstracts, and online content to identify reports of ADRs, safety signals, or other pertinent information. This surveillance is essential for detecting previously unknown adverse reactions or risks that may not have emerged during

Automation of Literature Monitoring for Pharmacovigilance Read More »

ZaZiBoNa significance for pharmaceutical companies in SADC

What ZaZiBoNa Means for Pharma Companies Targeting the SADC Market 

All Category, Blogs, regulatory /

For pharmaceutical companies eyeing expansion into the Southern African region, understanding the regulatory processes of 16 different countries can be a costly, time-consuming, and resource-intensive endeavor. But what if there was a way to streamline this process reducing approval times, harmonizing requirements, and unlocking simultaneous market access across multiple nations? Enter ZaZiBoNa, a collaborative medicines

What ZaZiBoNa Means for Pharma Companies Targeting the SADC Market  Read More »

QbD, RBQM, and RBM in Pharma and Clinical Research in 2025

Regulatory Perspectives on QbD, RBQM, and RBM in Pharma and Clinical Research 

All Category, Blogs, regulatory /

Why are pharma and clinical trial leaders doubling down on QbD, RBQM, and RBM in 2025? Because “compliance” is no longer enough, today, regulators expect quality, risk-awareness, and strategy to be embedded from the very beginning.  From decentralized trials to AI-driven insights, the pace of change is rapid—and so are the expectations from regulators like

Regulatory Perspectives on QbD, RBQM, and RBM in Pharma and Clinical Research  Read More »

Artificial Intelligence (AI) in Life Sciences: Ethics, Regulatory Frameworks, and Governance for Responsible Innovation 

All Category, Blogs, regulatory /

The integration of Artificial Intelligence (AI) in the life sciences sector has ushered in a new era of innovation enabling precision drug discovery, streamlining clinical trial operations, automating regulatory workflows, and personalizing therapeutic interventions. However, as AI capabilities advance, so do the ethical concerns, regulatory scrutiny, and governance challenges surrounding its responsible deployment.  This article

Artificial Intelligence (AI) in Life Sciences: Ethics, Regulatory Frameworks, and Governance for Responsible Innovation  Read More »

Quasi Drugs in Japan and South Korea

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea 

All Category, Blogs, Regulatory /

In the dynamic Asia-Pacific market, quasi drugs represent a unique regulatory category that bridges the gap between cosmetics and pharmaceuticals. Particularly in Japan and South Korea, quasi drugs have gained traction for their hybrid benefits offering therapeutic claims while maintaining a relatively simpler regulatory pathway compared to full-fledged drugs.    Understanding the regulatory and commercial

Quasi Drugs: Regulatory & Commercial Considerations for Japan and South Korea  Read More »